NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50242-0260-86 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use | |
50242-0333-01 | 50242-0333 | Trastuzumab | Herceptin | Immunotherapy | Monoclonal Antibody | HER2 | Feb 10, 2017 | Feb 10, 2017 | No Longer Used | ||
50242-0623-42 | 50242-0623 | ENTRECTINIB | Rozlytrek | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Oct 20, 2023 | In Use | |
50242-0717-01 | 50242-0717 | Cobimetinib | Cotellic | 20.0 mg/1 | Chemotherapy | MAPK/MEK Inhibitor | BRAF | Oral | Nov 10, 2015 | In Use | |
50242-0717-86 | 50242-0717 | Cobimetinib | Cotellic | 20.0 mg/1 | Chemotherapy | MAPK/MEK Inhibitor | BRAF | Oral | Nov 10, 2015 | In Use | |
50242-0917-01 | 50242-0917 | Atezolizumab | Tecentriq | 1200.0 mg/20mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | May 18, 2016 | In Use | |
50242-0917-86 | 50242-0917 | Atezolizumab | Tecentriq | 1200.0 mg/20mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Aug 11, 2016 | In Use | |
50242-0918-01 | 50242-0918 | Atezolizumab | TECENTRIQ | 840.0 mg/14mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Mar 8, 2019 | In Use | |
50242-0918-86 | 50242-0918 | Atezolizumab | TECENTRIQ | 840.0 mg/14mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Mar 8, 2019 | Mar 18, 2019 | In Use |
50242-0933-01 | 50242-0933 | Atezolizumab and hyaluronidase-tqjs | Tecentriq Hybreza | 1875.0 mg/15mL, 30000.0 U/15mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Subcutaneous | Sep 12, 2024 | In Use | |
50242-0933-86 | 50242-0933 | Atezolizumab and hyaluronidase-tqjs | Tecentriq Hybreza | 1875.0 mg/15mL, 30000.0 U/15mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Subcutaneous | Sep 12, 2024 | In Use | |
50268-0075-15 | 50268-0075 | ANASTROZOLE | ANASTROZOLE | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct 11, 2019 | In Use | ||
50268-0154-13 | 50268-0154 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 12, 2018 | In Use | |
50268-0290-11 | 50268-0290 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Sep 30, 2014 | Mar 19, 2018 | No Longer Used | |
50268-0290-15 | 50268-0290 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec 12, 2014 | Mar 19, 2018 | No Longer Used | |
50268-0291-11 | 50268-0291 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sep 30, 2014 | Mar 19, 2018 | No Longer Used | |
50268-0291-15 | 50268-0291 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec 12, 2014 | Mar 19, 2018 | No Longer Used | |
50268-0292-11 | 50268-0292 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sep 30, 2014 | Mar 19, 2018 | No Longer Used | |
50268-0292-15 | 50268-0292 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec 12, 2014 | Mar 19, 2018 | No Longer Used | |
50268-0314-15 | 50268-0314 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 23, 2019 | In Use | |
50268-0323-11 | 50268-0323 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 21, 2011 | Jul 31, 2019 | In Use |
50268-0323-15 | 50268-0323 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 21, 2011 | Jul 31, 2019 | In Use |
50268-0405-15 | 50268-0405 | Hydrocortisone | HYDROCORTISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 31, 2023 | In Use | |
50268-0406-15 | 50268-0406 | Hydrocortisone | HYDROCORTISONE | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 31, 2023 | In Use | |
50268-0407-15 | 50268-0407 | Hydrocortisone | HYDROCORTISONE | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 31, 2023 | In Use |
Found 11465 results — Export these results